2. Search Result
Search Result
Results for "

podophyllotoxin derivative

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N1977
    Podophyllotoxin glucoside

    		Others Cancer
    Podophyllotoxin glucoside is a podophyllotoxin derivative, has anti-tumor effects .
    Podophyllotoxin glucoside
  • HY-13761
    Teniposide
    5+ Cited Publications

    VM26

    		 Topoisomerase Cancer
    Teniposide is a podophyllotoxin derivative, acts as a topoisomerase II inhibitor, and used as a chemotherapeutic agent.
    Teniposide
  • HY-N2500
    Deoxypodophyllotoxin

    		Microtubule/Tubulin Apoptosis Autophagy Infection Cardiovascular Disease
    Deoxypodophyllotoxin (DPT), a derivative of podophyllotoxin, is a lignan with potent antimitotic, anti-inflammatory and antiviral properties isolated from Anthriscus sylvestris. Deoxypodophyllotoxin, targets the microtubule, has a major impact in oncology not only as anti-mitotics but also as potent inhibitors of angiogenesis . Deoxypodophyllotoxin induces cell autophagy and apoptosis . Deoxypodophyllotoxin evokes increase of intracellular Ca 2+ concentrations in DRG neurons .
    Deoxypodophyllotoxin
  • HY-N7685
    Podophyllol

    		Others Cancer
    Podophyllol, a derivative of podophyllotoxin esters, has antitumor activity .
    Podophyllol
  • HY-13761R
    Teniposide (Standard)

    		Topoisomerase Cancer
    Teniposide (Standard) is the analytical standard of Teniposide. This product is intended for research and analytical applications. Teniposide is a podophyllotoxin derivative, acts as a topoisomerase II inhibitor, and used as a chemotherapeutic agent.
    Teniposide (Standard)
  • HY-156088
    SSE1806

    		Microtubule/Tubulin Apoptosis Cancer
    SSE1806 is a derivative of podophyllotoxin (a natural antimitotic agent) and a microtubule/tubulin inhibitor with significant anticancer and antiproliferative activities. The GI50 of SSE1806 on cancer cell growth ranges from 1.29-21.15 μM. SSE1806 causes mitotic abnormalities and G2/M phase arrest, increases p53 expression, and inhibits colon cancer organoid growth. SSE1806 is able to overcome multidrug resistance in cell lines overexpressing MDR-1 .
    SSE1806

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: